GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

Phase 1

Completed

Conditions: RSV Infection

Interventions: Drug: GS-5806

First Posted Date: 2013-02-28

Last Posted Date: 2013-06-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 8

Registration Number: NCT01801293

Locations: 🇺🇸
Investigational Site, Madison, Wisconsin, United States

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase 2

Terminated

Conditions: Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Non-FL Indolent Non-Hodgkin's Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: Entospletinib MM
Drug: Entospletinib SDD

First Posted Date: 2013-02-27

Last Posted Date: 2020-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 326

Registration Number: NCT01799889

Locations: 🇺🇸
Memorial Cancer Institute, Hollywood, Florida, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 45 locations

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Phase 3

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: E/C/F/TAF
Drug: E/C/F/TDF
Drug: E/C/F/TDF Placebo
Drug: E/C/F/TAF Placebo

First Posted Date: 2013-02-22

Last Posted Date: 2020-03-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 872

Registration Number: NCT01797445

Locations: 🇺🇸
Kaiser Permanente - Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
Mercer University, Macon, Georgia, United States

and more 113 locations

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

Phase 1

Withdrawn

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: GS-5806
Drug: Placebo

First Posted Date: 2013-02-22

Last Posted Date: 2013-10-28

Lead Sponsor: Gilead Sciences

Registration Number: NCT01797419

Locations: 🇦🇺
Geelong Hospital, Geelong, Victoria, Australia
🇦🇺
Monash Medical Center, Clayton, Australia
🇦🇺
Queensland Children's Medical Research Unit, Herston, Australia

and more 6 locations

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Indolent Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Drug: Entospletinib
Drug: Idelalisib

First Posted Date: 2013-02-21

Last Posted Date: 2020-06-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 66

Registration Number: NCT01796470

Locations: 🇺🇸
University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States
🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸
Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States

and more 10 locations

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Phase 1

Terminated

Conditions: Cystic Fibrosis
Chronic Obstructive Pulmonary Disease

Interventions: Drug: GS-5737

First Posted Date: 2013-02-15

Last Posted Date: 2014-03-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 7

Registration Number: NCT01793649

Locations: 🇺🇸
Investigational Site, Chapel Hill, North Carolina, United States

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Phase 3

Completed

Conditions: Human Immunodeficiency Virus
Chronic Hepatitis C

Interventions: Drug: Sofosbuvir
Drug: RBV

First Posted Date: 2013-02-05

Last Posted Date: 2015-04-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 275

Registration Number: NCT01783678

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Phase 3

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: E/C/F/TAF
Drug: E/C/F/TDF
Drug: E/C/F/TAF Placebo
Drug: E/C/F/TDF Placebo

First Posted Date: 2013-01-31

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 872

Registration Number: NCT01780506

Locations: 🇺🇸
Kaiser Permanente Los Angeles, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Mercer University School of Medicine, Macon, Georgia, United States

and more 114 locations

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Conditions: Post-transplant Hepatitis C

First Posted Date: 2013-01-30

Last Posted Date: 2014-01-16

Lead Sponsor: Gilead Sciences

Registration Number: NCT01779518

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: GS-4774

First Posted Date: 2013-01-30

Last Posted Date: 2014-01-08

Lead Sponsor: Gilead Sciences

Target Recruit Count: 60

Registration Number: NCT01779505

Locations: 🇺🇸
Celerion, Phoenix, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy